Table 4.
The changes in treatment response parameters in the ACO and pure asthma group after 6 months of treatment with biologics.
| Variables | ACO (n = 13) | Pure asthma (n = 81) | P-value |
|---|---|---|---|
| ΔFEV1 (L) | 0.38 ± 0.67 (n = 13) | 0.32 ± 0.42 (n = 81) | 0.649 |
| ΔFEV1 (%) | 10.7 ± 17.2 (n = 13) | 11.3 ± 12.9 (n = 81) | 0.652 |
| ΔFEV1/FVC | 0.03 ± 0.06 (n = 13) | 0.03 ± 0.09 (n = 80) | 0.959 |
| ΔACT | 3.3 ± 5.5 (n = 13) | 5.4 ± 5.4 (n = 79) | 0.290 |
| ΔBudesonide equivalent ICS dose (mcg/day) | −66.7 ± 460.0 (n = 13) | −17.9 ± 236.2 (n = 75) | 0.912 |
| ΔPrednisolone equivalent OCS maintenance dose (mg) | −117.5 ± 94.4 (n = 4) | −115.1 ± 456.9 (n = 7) | 0.415 |
| ΔFeNO (ppb) | −18.6 ± 24.7 (n = 13) | −14.7 ± 45.4 (n = 77) | 0.688 |
| ΔBlood eosinophil (/μL) | −36.5 ± 517.0 (n = 13) | −363.2 ± 1294.6 (n = 78) | 0.013 |
| ΔSputum eosinophil (%) | −3.4 ± 10.6 (n = 5) | −14.5 ± 24.0 (n = 31) | 0.065 |
| ΔNumber of exacerbation | −0.96 ± 2.47 | −1.40 ± 2.63 | 0.575 |
The changes (Δ) were calculated by 6 M − baseline. P-value was calculated by the Wilcoxon rank sum test for continuous variables. Abbreviations: ACO, Asthma-COPD Overlap; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ACT, Asthma Control Test; ICS, inhaled corticosteroids; OCS, oral corticosteroids; FeNO, fractional exhaled nitric oxide.